… Gefitinib, erlotinib and afatinib are three widely used … ) for treating advanced non-small cell
lung cancer (NSCLC) with proven … Gefitinib and erlotinib demonstrated comparable effects on …

… -small cell lung cancer (NSCLC). We demonstrated that erlotinib and gefitinib have similar
activity … profiles, with a suggestion of better tolerability for gefitinib. The analysis suggests that …

… Erlotinib was prescribed more frequently than gefitinib in … EGFR, the effectiveness of gefitinib
and erlotinib, including drug … drug selection between erlotinib and gefitinib in clinical practice…

… A phase III trial was conducted to compare the safety and efficacy of erlotinib with that of
gefitinib in advanced non-small cell lung cancer harbouring epidermal growth factor receptor …

… , gefitinib and erlotinib, have changed the treatment paradigm of advanced non-small … lung
cancer (NSCLC). Many phase II or III studies have proven the efficacy of gefitinib or erlotinib …

… Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC). Interstitial lung …

… for use of erlotinib, as for gefitinib. By comparison with PFS for gefitinib (10.4 months in
NEJ002 and 9.2 months in WJTOG), a median PFS of 13.1 months with erlotinib in OPTIMAL is …

… Erlotinib and gefitinib are reversible EGFR-TKIs, while … comparing the efficacy of gefitinib
and erlotinib in second-line … LUX-Lung 7 trial comparing the efficacy of afatinib and gefitinib in …

… of erlotinib are higher than those of gefitinib, which supports the view that patients can achieve
longer PFS with erlotinib treatment than with gefitinib and that erlotinib can … , than gefitinib. …

… our lung cancer patients to compare the benefits derived from erlotinib and gefitinib and to
… We subsequently analyzed tumor tissue from a subgroup of these patients for a pilot study to …